In this article, we will discuss Dinutuximab (Dosage Overview). So, let’s get started.
Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of
pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Verify that patients have adequate hematologic, respiratory, hepatic, and renal function prior to initiating each course of Unituxin.
Administer required premedication and hydration prior to initiation of each Unituxin infusion.
The recommended dose of Unituxin is 17.5 mg/m²/day administered as an intravenous
infusion over 10 to 20 hours for 4 consecutive days for a maximum of 5 cycles.
Initiate at an infusion rate of 0.875 mg/m²/hour for 30 minutes. The infusion rate can be gradually increased as tolerated to a maximum rate of 1.75 mg/m²/hour.